Paul Denker, MD
Endocrinology, Diabetes & Metabolism · Palm Harbor, FLNPI 1750328811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 901 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 901 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- Amgen$1K
- AstraZeneca$1K
- Boehringer Ingelheim$948
- plus $8K from 54 others
Across 283 payments — averaging $805.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$156K
- Pfizer$34K
- Sanofi US Services Inc.$27K
- Lexicon Pharmaceuticals, Inc.$12K
What the payments were for
- Speaking & faculty fees$500%
- Food & beverage$17,09499%
- Education$850%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,288 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 156 | $197,165 |
| OzempicSemaglutide | 142 | $193,726 |
| JardianceEmpagliflozin | 90 | $103,669 |
| TrulicityDulaglutide | 29 | $36,114 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $23,379 |
| FarxigaDapagliflozin Propanediol | 23 | $23,032 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $22,755 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $20,124 |
| XyostedTestosterone Enanthate | 13 | $11,795 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,969 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $10,437 |
| Novolog FlexpenInsulin Aspart | 37 | $10,103 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $9,576 |
| Liraglutide | 12 | $8,366 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 13 | $6,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,541 | $237,695199 claims |
| Novo NordiskOzempic | $2,643 | $193,726142 claims |
| Boehringer IngelheimJardiance | $948 | $103,66990 claims |
| AstraZenecaFarxiga | $1,157 | $23,03223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,379 | $12,42226 claims |
| Antares Pharma, Inc.Xyosted | $374 | $11,79513 claims |
| AbbVieSynthroid | $85 | $5,09255 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $315 | $2,753233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Palm Harbor
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.